Breakthrough Therapies Fuel Monoclonal Antibodies Market Growth

The monoclonal antibodies market size is expected to be valued at USD 43.35 Billion in 2024 and reach USD 56.12 Billion by 2029, growing at a CAGR of 5.3 % from 2024 to 2029.

Monoclonal antibodies (mAbs) are synthetic molecules created in laboratories to imitate the immune system's natural defense against harmful pathogens like viruses or bacteria. These molecules are developed to selectively bind to particular targets, such as proteins or other molecules, to either inhibit their function or enhance them for elimination by the immune system. These are used in several medical treatments, such as cancer, autoimmune diseases, infectious diseases, and transplant rejection.

Global Monoclonal Antibodies Market Report Scope:

• Market Size (2029): USD 56.12 Billion
• Market Size (2024): USD 43.35 Billion
• CAGR (2024 to 2029): 5.3 %
• Base Year: 2023
• Forecast Period: 2024 to 2029
• Segments Analysed: By Source, Indication, End User, Application, and Region
• Geographies Covered: North America, Europe, APAC, Latin America, and Middle East & Africa
• Key Market Players Profiled: GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly, And Shanghai Junshi Bioscience Co., Ltd.Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Lt., are playing a dominant role in the monoclonal antibodies market.

Browse full details of the report @ https://www.marketdataforecast.com/market-reports/global-monoclonal-antibodies-market

Key Insights from The Report:

• Based on Source, the murine segment captured highest share of the global market in 2023.
• Based on Indication, the cancer disease segment dominated the market in 2023.
• Based on End User, the hospitals /clinics segment dominated the market in 2023.
• Based on Application, the medical segment dominated the market in 2023.

• North America dominated the healthcare analytics market in 2023. Europe accounted for second-highest share of the global monoclonal antibodies market in 2023 and on the other hand, the Asia-Pacific region is estimated to grow at the fastest CAGR during the forecast period.
• AMD Global monoclonal antibodies market, GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly, And Shanghai Junshi Bioscience Co., Ltd.Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Lt.are dominated the monoclonal antibodies market.

The growing prevalence of various autoimmune and chronic diseases, the increasing geriatric population, and the rising incidence of cancer cases across the world are majorly contributing to the global monoclonal antibodies market growth. Manufacturers are focusing on developing medications across different classes to address a range of disorders, from cancer to rare diseases; investing in R&D activities is boosting the global market expansion. The combination of monoclonal antibodies with chemotherapy drugs is increasingly used in the treatment of various cancers. Monoclonal antibodies have revolutionized the laboratory diagnosis of numerous diseases. They can serve as diagnostic reagents for biochemical analyses or as tools for disease diagnosis through imaging. All these benefits of monoclonal antibodies augment their adoption in the healthcare industry, enhancing the market size.

Monoclonal antibodies are generally more cost-effective than the traditional medicines fueling global market expansion. The extensive use of monoclonal antibodies in various end-use sectors, including molecular biology, medicine, and biochemistry, is estimated to provide market growth opportunities during the forecast period. Monoclonal antibody therapeutics are highly adopted in the U.S. and Europe, which is majorly driving global revenue growth. The growing awareness among people and healthcare professionals regarding the benefits and applications of monoclonal antibodies is escalating the market growth opportunities. The COVID-19 pandemic has increased the market expansion prospects by fueling the development of various monoclonal antibodies against the COVID-19 virus.

Monoclonal antibody therapies are associated with high costs, restricting access for certain patients and healthcare organizations, particularly in low and middle-income regions, and limiting market growth. The increasing competition by biosimilars is expected to hamper expanding the global monoclonal antibodies market. The development and approval of monoclonal antibodies are subjected to stringent regulations, which slow down the process by raising costs and the market size growth. Some patients may exhibit immune responses to monoclonal antibodies, which reduce their effectiveness or trigger adverse reactions, limiting the adoption of monoclonal antibodies.

SEGMENTATION INCLUDED IN THIS REPORT:

By Source:
• Murine
• Chimeric
• Humanized
• Human
By Indication:
• Cancer
o Blood Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Pancreatic Cancer
o Others
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Others)
By End-User:
• Hospitals/Clinics
• Research Institute
• Diagnostic Laboratories
By Application:
• Medical
• Experimental
• Western Blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others
By Region:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Browse Regional Reports:

North America Monoclonal Antibodies Market Research Report - Segmented By Source, Indication, End-User, Application, Country (U.S, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/north-america-monoclonal-antibodies-market

Europe Monoclonal Antibodies Market Research Report - Segmented By Source, Indication, End-User, Application, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/europe-monoclonal-antibodies-market

APAC Monoclonal Antibodies Market Research Report - Segmented By Source, Indication, End-User, Application, Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2023 to 2028) - https://www.marketdataforecast.com/market-reports/asia-pacific-monoclonal-antibodies-market

Latin America Monoclonal Antibodies Market Research Report - Segmented By Source, Indication, End-User, Application, Country (Mexico, Brazil, Argentina, Chile and Rest of Latin America) - Industry Analysis, Size,Share, Growth, Trends, & Forecast (2023 to 2028) -https://www.marketdataforecast.com/market-reports/latin-america-monoclonal-antibodies-market

Middle East & Africa Monoclonal Antibodies Market Research Report - Segmented By Source, Indication, End-User, Application, Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan and Rest of MEA) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast from 2023 to 2028 - https://www.marketdataforecast.com/market-reports/middle-east-and-africa-monoclonal-antibodies-market

TABLE OF CONTENTS:

1. Introduction

1.1 MarketDefinition

1.2 StudyDeliverables

1.3 BaseCurrency,BaseYearandForecastPeriods

1.4 GeneralStudyAssumptions

2. ResearchMethodology

2.1 Introduction

2.2 ResearchPhases

2.2.1 SecondaryResearch

2.2.2 PrimaryResearch

2.2.3 EconometricModelling

2.2.4 ExpertValidation

2.3 AnalysisDesign

2.4 StudyTimeline

3. Overview

3.1 ExecutiveSummary

3.2 KeyInferences

4. Drivers,Restraints,Opportunities,andChallengesAnalysis(DROC)

4.1 MarketDrivers

4.2 MarketRestraints

4.3 KeyChallenges

4.4 CurrentOpportunitiesintheMarket

5. MarketSegmentation

5.1 BySource

5.1.1 Murine

5.1.2 Chimeric

5.1.3 Humanized

5.1.4 Human

5.2 ByIndication

5.2.1 Cancer

5.2.1.1 BloodCancer

5.2.1.2 BreastCancer

5.2.1.3 ColorectalCancer

5.2.1.4 LungCancer

5.2.1.5 PancreaticCancer

5.2.1.6 Others

5.2.2 AutoimmuneDiseases

5.2.3 InfectiousDiseases

5.2.4 CardiovascularDiseases

5.2.5 CNSDisorders

5.2.6 Others(Inflammatory,MicrobialDiseases,&Other)

5.3 EndUser

5.3.1 Hospitals/Clinics

5.3.2 ResearchInstitute

5.3.3 DiagnosticLaboratories

5.4 Application

5.4.1 Medical

5.4.2 Experimental

5.4.2.1 WesternBlot

5.4.2.2 ELISA

5.4.2.3 RadioimmuneAssays

5.4.2.4 Immunofluorescence

5.4.2.5 Other(Immunohistochemistry,Immunoprecipitation,&Immunocytochemistry)

6. GeographicalAnalysis

6.1 NorthAmerica

6.1.1 Introduction

6.1.2 UnitedStates

6.1.3 Canada

6.2 Europe

6.2.1 Introduction

6.2.2 U.K

6.2.3 Spain

6.2.4 Germany

6.2.5 Italy

6.2.6 France

6.3 Asia-Pacific

6.3.1 Introduction

6.3.2 China

6.3.3 India

6.3.4 Japan

6.3.5 SouthKorea

6.3.6 Australia

6.4 LatinAmerica

6.4.1 Introduction

6.4.2 Brazil

6.4.3 Argentina

6.4.4 Mexico

6.5 MiddleEast&Africa

6.5.1 Introduction

6.5.2 Middle-East

6.5.3 Africa

7. PipelineProductAnalysis

7.1 Overview

7.2 PipelineDevelopmentLandscape

7.3 MolecularTargetsinthePipeline

7.4 ClinicalTrials

7.4.1ClinicalTrialDurationbyStageofDevelopment,Indication,MoleculeTypeandMolecularTarget

7.4.2 ClinicalTrialSizebyStageofDevelopment,Indication,MoleculeTypeandMolecularTarget

7.5 KeyTrendsinMonoclonalAntibodiesDevelopment

7.5.1 TargetedTherapies

7.6 PromisingMonoclonalAntibodiesinPipeline

7.7 HeatMapofSafetyandEfficacyforPipelineandMarketedMonoclonalAntibodies

8. StrategicAnalysis

8.1 PESTLEanalysis

8.1.1 Political

8.1.2 Economic

8.1.3 Social

8.1.4 Technological

8.1.5 Legal

8.1.6 Environmental

8.2 Porter'sFiveanalysis

8.2.1 BargainingPowerofSuppliers

8.2.2 BargainingPowerofConsumers

8.2.3 ThreatofNewEntrants

8.2.4 ThreatofSubstituteProductsandServices

8.2.5 CompetitiveRivalrywithintheIndustry

9. MarketLeaders'Analysis

9.1 GlaxoSmithKlineplc(U.K.)

9.1.1 Overview

9.1.2 ProductAnalysis

9.1.3 Financialanalysis

9.1.4 RecentDevelopments

9.1.5 SWOTanalysis

9.1.6 AnalystView

9.2 NovartisAG(Switzerland)

9.3 PfizerInc.(U.S.)

9.4 ThermoFisherScientificInc.(U.S.)

9.5 EliLillyandCompany(U.S.)

9.6 SeattleGenetics(U.S.)

9.7 Bristol-MyersSquibb(U.S.)

9.8 F.Hoffmann-LaRocheLtd.(Switzerland)

9.9 BiogenInc.(U.S.)

10. CompetitiveLandscape

10.1 Marketshareanalysis

10.2 MergerandAcquisitionAnalysis

10.3 Agreements,collaborationsandJointVentures

10.4 NewProductLaunches

11. Market Outlook&InvestmentOpportunities

Appendix

a) ListofTables

b) ListofFigure

Contact Us:
MarketDataForecast
www.marketdataforecast.com
Phone: +1-888-702-9626
Email: sales@marketdataforecast.com
5th Floor, Trendz Pride, Patrika Nagar Rd Number 1, HUDA Techno Enclave, HITEC City, Hyderabad, Telangana 500081, India

About Us:
Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients.

This release was published on openPR.